{"id":3169,"date":"2018-09-11T13:12:35","date_gmt":"2018-09-11T07:42:35","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=3169"},"modified":"2021-07-24T12:57:03","modified_gmt":"2021-07-24T07:27:03","slug":"notizia-72","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/notizia-72","title":{"rendered":"Notizia"},"content":{"rendered":"<p style=\"text-align: justify;\"><strong>Nucala of GlaxoSmithKline exhibits splendid benefits to other IL-5 Inhibitors in Asthma, however flunks as a COPD Drug<\/strong><\/p>\n<p style=\"text-align: justify;\">A Complete Response Letter is received by <strong>GSK<\/strong> from the <strong>U.S. Food and Drug Administration (FDA)<\/strong> for <strong>Nucala<\/strong> (mepolizumab) as <strong>COPD<\/strong> treatment. Nucala, which targets the <strong>IL-5 pathway<\/strong>, was initially approved in 2015 by the FDA to treat patients of age <strong>12<\/strong> years and older with severe asthma with an eosinophilic phenotype. Data by GSK was shown that the same medication was a better treatment in severe eosinophilic asthma in patients with similar blood eosinophil counts.<\/p>\n<p style=\"text-align: justify;\"><strong>The mutation in gene is an answer to glioblastoma\u2019s immortality <\/strong><\/p>\n<p style=\"text-align: justify;\">Researchers of the <strong>University of California<\/strong>, San Francisco discovered a common <a href=\"https:\/\/www.delveinsight.com\/report-store\/cervical-cancer-market\">cancer<\/a> mutation that drives <strong>glioblastoma<\/strong>, the <a href=\"https:\/\/www.delveinsight.com\/report-store\/brain-hemorrhage-pipeline-insight\">brain<\/a> cancer that could point new targets for drug treatments. The mutation, which occurs in a gene regulator called <strong>TERT<\/strong> and is the most common mutation in glioblastoma that leads to immortality in cancer cells.<\/p>\n<p style=\"text-align: justify;\"><strong>The novice startup,<\/strong> <strong>Elevian set up to chase the approach for aging diseases<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Elevian<\/strong> has established to develop drugs, which are based on <strong>GDF11<\/strong> (growth differentiation factor 11), a protein that is linked to age-related diseases, discovered by <strong>Harvard University<\/strong>. Organs can be rejuvenated by taking the blood from young mice and administered in older animals. The work of researches on GDF11 involved a technique, <strong>parabiosis<\/strong> in which the circulatory systems of young and old mice that were combined to allow the blood to flow between the animals that gives the cue that cardiac, brain and muscle tissue can be regenerated by injecting the protein into old mice.<\/p>\n<p style=\"text-align: justify;\"><strong>Pfizer joins Cytoo for help to identify Duchenne muscular dystrophy<\/strong> <strong>targets<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Pfizer<\/strong> has collaborated with <strong>Cytoo<\/strong> to work on <strong>Duchenne muscular dystrophy<\/strong> (DMD) target discovery platform. The <strong>early-stage<\/strong> alliance comes a week after Pfizer stopped the development of domagrozumab in DMD, due to lackluster midphase data. Inability of Domagrozumab to move the needle in <strong>phase 2<\/strong>, got added to the disturbed history of DMD drug development.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Nucala of GlaxoSmithKline exhibits splendid benefits to other IL-5 Inhibitors in Asthma, however flunks as a COPD Drug A Complete Response Letter is received by GSK from the U.S. Food and Drug Administration (FDA) for Nucala (mepolizumab) as COPD treatment. Nucala, which targets the IL-5 pathway, was initially approved in 2015 by the FDA to [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2465,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[718,1795,1797,1796,1790,704,1791,985,1787,1792,1794,1789,1793,460,1788,1786,1256],"industry":[17225],"therapeutic_areas":[17238,17228,17234,17243],"class_list":["post-3169","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-copd","tag-cytoo","tag-dmd","tag-duchenne-muscular-dystrophy","tag-elevian","tag-fda","tag-gdf11","tag-glaxosmithkline","tag-glioblastoma","tag-harvard-university","tag-il-5-pathway","tag-immortality","tag-nucala","tag-pfizer","tag-tert","tag-u-s-food-and-drug-administration-fda","tag-university-of-california","industry-pharmaceutical","therapeutic_areas-genetic-disorders","therapeutic_areas-oncology","therapeutic_areas-rare-diseases","therapeutic_areas-respiratory-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Notizia 11\/09\/2018 - DelveInsight Business Research LLP<\/title>\n<meta name=\"description\" content=\"A Complete Response Letter is received by GSK from the U.S. Food and Drug Administration (FDA) for Nucala (mepolizumab) as COPD treatment. Nucala,....\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-72\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Notizia 11\/09\/2018 - DelveInsight Business Research LLP\" \/>\n<meta property=\"og:description\" content=\"A Complete Response Letter is received by GSK from the U.S. Food and Drug Administration (FDA) for Nucala (mepolizumab) as COPD treatment. Nucala,....\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/notizia-72\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-09-11T07:42:35+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09021225\/Notizia.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1112\" \/>\n\t<meta property=\"og:image:height\" content=\"660\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Notizia 11\/09\/2018 - DelveInsight Business Research LLP","description":"A Complete Response Letter is received by GSK from the U.S. Food and Drug Administration (FDA) for Nucala (mepolizumab) as COPD treatment. Nucala,....","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/notizia-72","og_locale":"en_US","og_type":"article","og_title":"Notizia 11\/09\/2018 - DelveInsight Business Research LLP","og_description":"A Complete Response Letter is received by GSK from the U.S. Food and Drug Administration (FDA) for Nucala (mepolizumab) as COPD treatment. Nucala,....","og_url":"https:\/\/www.delveinsight.com\/blog\/notizia-72","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2018-09-11T07:42:35+00:00","article_modified_time":"2021-07-24T07:27:03+00:00","og_image":[{"width":1112,"height":660,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09021225\/Notizia.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-72","url":"https:\/\/www.delveinsight.com\/blog\/notizia-72","name":"Notizia 11\/09\/2018 - DelveInsight Business Research LLP","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-72#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-72#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09021225\/Notizia.png","datePublished":"2018-09-11T07:42:35+00:00","dateModified":"2021-07-24T07:27:03+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"A Complete Response Letter is received by GSK from the U.S. Food and Drug Administration (FDA) for Nucala (mepolizumab) as COPD treatment. Nucala,....","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/notizia-72"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-72#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09021225\/Notizia.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09021225\/Notizia.png","width":1112,"height":660,"caption":"transthyretin amyloidosis"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09021225\/Notizia-300x178.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">COPD<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Cytoo<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">DMD<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Duchenne muscular dystrophy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Elevian<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">GDF11<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">GlaxoSmithKline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">glioblastoma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Harvard University<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">IL-5 pathway<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">immortality<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Nucala<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pfizer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">TERT<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">U.S. Food and Drug Administration (FDA)<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">University of California<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">COPD<\/span>","<span class=\"advgb-post-tax-term\">Cytoo<\/span>","<span class=\"advgb-post-tax-term\">DMD<\/span>","<span class=\"advgb-post-tax-term\">Duchenne muscular dystrophy<\/span>","<span class=\"advgb-post-tax-term\">Elevian<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">GDF11<\/span>","<span class=\"advgb-post-tax-term\">GlaxoSmithKline<\/span>","<span class=\"advgb-post-tax-term\">glioblastoma<\/span>","<span class=\"advgb-post-tax-term\">Harvard University<\/span>","<span class=\"advgb-post-tax-term\">IL-5 pathway<\/span>","<span class=\"advgb-post-tax-term\">immortality<\/span>","<span class=\"advgb-post-tax-term\">Nucala<\/span>","<span class=\"advgb-post-tax-term\">Pfizer<\/span>","<span class=\"advgb-post-tax-term\">TERT<\/span>","<span class=\"advgb-post-tax-term\">U.S. Food and Drug Administration (FDA)<\/span>","<span class=\"advgb-post-tax-term\">University of California<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 8 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Sep 11, 2018","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Sep 11, 2018 1:12 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"transthyretin amyloidosis","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3169","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=3169"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3169\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/2465"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=3169"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=3169"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=3169"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=3169"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=3169"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}